Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function

References

• Sakr Y, Jaschinski U, Wittebole X, et al. Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit. Open Forum Infect Dis. 2018;5(12):ofy313. doi:10.1093/ofid/ofy313
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810. doi:10.1001/jama.2016.0287
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377. doi:10.1007/s00134-017-4683-6
   PubMed Web of Science ®Google Scholar
• Liu VX, Fielding-Singh V, Greene JD, et al. The timing of early antibiotics and hospital mortality in sepsis. Am J Respir Crit Care Med. 2017;196(7):856–863. doi:10.1164/rccm.201609-1848OC
   PubMed Web of Science ®Google Scholar
• Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072–1083. doi:10.1093/cid/ciu027
   PubMed Web of Science ®Google Scholar
• Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840–851; quiz 859. doi:10.1097/CCM.0b013e3181961bff
   Web of Science ®Google Scholar
• Taccone FS, Laterre PF, Dugernier T, et al. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Critical Care. 2010;14(4):R126. doi:10.1186/cc9091
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498–509. doi:10.1016/S1473-3099(14)70036-2
   PubMed Web of Science ®Google Scholar
• Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Societe Francaise de Pharmacologie et Therapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Societe Francaise d’Anesthesie et Reanimation-SFAR). Critical Care. 2019;23(1):104. doi:10.1186/s13054-019-2378-9
   PubMed Web of Science ®Google Scholar
• Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther. 2004;26(8):1187–1198. doi:10.1016/S0149-2918(04)80001-8
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020;46(6):1127–1153. doi:10.1007/s00134-020-06050-1
   PubMed Web of Science ®Google Scholar
• Ehmann L, Zoller M, Minichmayr IK, et al. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study. Critical Care. 2017;21(1):263. doi:10.1186/s13054-017-1829-4
   PubMed Web of Science ®Google Scholar
• Burger R, Guidi M, Calpini V, et al. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. J Antimicrob Chemother. 2018;73(12):3413–3422. doi:10.1093/jac/dky370
   PubMed Web of Science ®Google Scholar
• Tamatsukuri T, Ohbayashi M, Kohyama N, et al. The exploration of population pharmacokinetic model for meropenem in augmented renal clearance and investigation of optimum setting of dose. J Infect Chemother. 2018;24(10):834–840. doi:10.1016/j.jiac.2018.07.007
   PubMed Web of Science ®Google Scholar
• Petersson J, Giske CG, Eliasson E. Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients. Acta Anaesthesiol Scand. 2016;60(10):1425–1436. doi:10.1111/aas.12808
   PubMed Web of Science ®Google Scholar
• Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis Suppl. 1995;96:11–16.
   PubMedGoogle Scholar
• Dhaese SAM, Farkas A, Colin P, et al. Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models. J Antimicrob Chemother. 2019;74(2):432–441. doi:10.1093/jac/dky434
   Web of Science ®Google Scholar
• Muller AE, Huttner B, Huttner A. Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections? Drugs. 2018;78(4):439–451. doi:10.1007/s40265-018-0880-z
   PubMed Web of Science ®Google Scholar
• Tabah A, De Waele J, Lipman J, et al. The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother. 2015;70(9):2671–2677. doi:10.1093/jac/dkv165
   PubMed Web of Science ®Google Scholar
• Minichmayr IK, Roberts JA, Frey OR, Roehr AC, Kloft C, Brinkmann A. Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model. J Antimicrob Chemother. 2018;73(5):1330–1339. doi:10.1093/jac/dkx526
   PubMed Web of Science ®Google Scholar
• Idoate Grijalba AI, Aldaz Pastor A, Marquet P, Woillard JB. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation. Eur J Clin Pharmacol. 2019;75(10):1405–1414. doi:10.1007/s00228-019-02716-y
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228. doi:10.1007/s00134-012-2769-8
   PubMed Web of Science ®Google Scholar
• Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31(4):1250–1256. doi:10.1097/01.CCM.0000050454.01978.3B
   PubMed Web of Science ®Google Scholar
• Bilbao-Meseguer I, Rodriguez-Gascon A, Barrasa H, Isla A, Solinis MA. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107–1121. doi:10.1007/s40262-018-0636-7
   PubMed Web of Science ®Google Scholar
• Gijsen M, Dreesen E, Annaert P, et al. Meropenem pharmacokinetics and target attainment in critically ill patients are not affected by extracorporeal membrane oxygenation: a matched cohort analysis. Microorganisms. 2021;9(6):1310. doi:10.3390/microorganisms9061310
   Web of Science ®Google Scholar
• Mortensen JS, Jensen BP, Zhang M, Doogue M. Preanalytical stability of piperacillin, tazobactam, meropenem, and ceftazidime in plasma and whole blood using liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2019;41(4):538–543. doi:10.1097/FTD.0000000000000650
   PubMed Web of Science ®Google Scholar
• Colin P, De Bock L, T’Jollyn H, Boussery K, Van Bocxlaer J. Development and validation of a fast and uniform approach to quantify beta-lactam antibiotics in human plasma by solid phase extraction-liquid chromatography-electrospray-tandem mass spectrometry. Talanta. 2013;103:285–293. doi:10.1016/j.talanta.2012.10.046
   PubMed Web of Science ®Google Scholar
• Gijsen M, Filtjens B, Annaert P, et al. Meropenem stability in human plasma at −20 degrees C: detailed assessment of degradation. Antibiotics. 2021;10(4):449.
   Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. Testing Breakpoint tables for interpretation of MICs and zone diameters; 2020. Accessed on March 24, 2021.
   Google Scholar
• Gijsen M, Huang CY, Flechet M, et al. Development and external validation of an online clinical prediction model for augmented renal clearance in adult mixed critically ill patients: the augmented renal clearance predictor. Crit Care Med. 2020;48(12):e1260–e1268. doi:10.1097/CCM.0000000000004667
   Web of Science ®Google Scholar
• Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. J Open Source Softw. 2019;4(43):1686. doi:10.21105/joss.01686
   Google Scholar
• Wickham H. Ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag; 2016.
   Google Scholar
• Goncalves-Pereira J, Silva NE, Mateus A, Pinho C, Povoa P. Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients. BMC Pharmacol Toxicol. 2014;15:21. doi:10.1186/2050-6511-15-21
   PubMed Web of Science ®Google Scholar
• Mattioli F, Fucile C, Del Bono V, et al. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Eur J Clin Pharmacol. 2016;72(7):839–848. doi:10.1007/s00228-016-2053-x
   PubMed Web of Science ®Google Scholar
• Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64(1):142–150. doi:10.1093/jac/dkp139
   PubMed Web of Science ®Google Scholar
• Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med. 2011;37(4):632–638. doi:10.1007/s00134-010-2105-0
   PubMed Web of Science ®Google Scholar
• Sjovall F, Alobaid AS, Wallis SC, Perner A, Lipman J, Roberts JA. Maximally effective dosing regimens of meropenem in patients with septic shock. J Antimicrob Chemother. 2018;73(1):191–198. doi:10.1093/jac/dkx330
   PubMed Web of Science ®Google Scholar
• Alobaid AS, Wallis SC, Jarrett P, et al. Effect of obesity on the population pharmacokinetics of meropenem in critically ill patients. Antimicrob Agents Chemother. 2016;60(8):4577–4584. doi:10.1128/AAC.00531-16
   Web of Science ®Google Scholar
• Tsai D, Stewart P, Goud R, et al. Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis. Int J Antimicrob Agents. 2016;48(5):542–546. doi:10.1016/j.ijantimicag.2016.08.015
   PubMed Web of Science ®Google Scholar
• Carlier M, Dumoulin A, Janssen A, et al. Comparison of different equations to assess glomerular filtration in critically ill patients. Intensive Care Med. 2015;41(3):427–435. doi:10.1007/s00134-014-3641-9
   PubMed Web of Science ®Google Scholar